Keros Therapeutics, Inc.
KROS
$18.10
$1.277.55%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 86.25% | 32.17% | 444.32% | -14.37% | -34.27% |
| Total Depreciation and Amortization | 25.80% | 20.92% | 24.19% | 34.41% | 49.52% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -51.01% | -0.09% | 12.34% | 27.59% | 3.62% |
| Change in Net Operating Assets | -56.60% | -111.50% | 128.91% | -246.64% | 435.49% |
| Cash from Operations | 110.65% | 25.57% | 461.69% | -80.71% | 10.25% |
| Capital Expenditure | 65.80% | -132.26% | 40.27% | 46.58% | 29.82% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 65.80% | -132.26% | 40.27% | 46.58% | 29.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.91% | -99.53% | -100.00% | 8.98% | 50,084.57% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | -381.48% |
| Cash from Financing | -99.91% | -99.52% | -100.00% | 9.08% | 54,809.86% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -97.40% | 17.10% | 44.31% | -32.38% | 465.15% |